Ignite Creation Date:
2024-05-06 @ 2:55 AM
Last Modification Date:
2024-10-26 @ 11:25 AM
Study NCT ID:
NCT02152943
Status:
COMPLETED
Last Update Posted:
2020-12-19
First Post:
2014-05-29
Brief Title:
Everolimus Letrozole and Trastuzumab in HR- and HER2Neu-positive Patients
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Malignant Solid Neoplasm |
| Estrogen Receptor Positive |
| HER2Neu Positive |
| Postmenopausal |
| Premenopausal |
| Progesterone Receptor Positive |
| Recurrent Breast Carcinoma |
| Refractory Breast Carcinoma |
| Refractory Hormone Receptor Positive Breast Carcinoma |
| Stage IIIA Breast Cancer AJCC v7 |
| Stage IIIB Breast Cancer AJCC v7 |
| Stage IIIC Breast Cancer AJCC v7 |
| Stage IV Breast Cancer AJCC v6 and v7 |
Keywords: